Sandrine Faivre

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.1K citations · Full text

Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation

Y. Pointreau, P. Garaud, S. Chapet et al. · JNCI Journal of the National Cancer Institute · 2009 · 563 citations

Oxaliplatin: mechanism of action and antineoplastic activity.

Éric Raymond, Sandrine Faivre, Jan M. Woynarowski et al. · PubMed · 1998 · 523 citations

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell, Sandrine Faivre, Howard A. Burris et al. · Journal of Clinical Oncology · 2008 · 476 citations